Cargando…
Extracellular volume quantification in isolated hypertension - changes at the detectable limits?
BACKGROUND: Diffuse myocardial fibrosis (DMF) is important in cardiovascular disease, however until recently could only be assessed by invasive biopsy. We hypothesised that DMF measured by T1 mapping is elevated in isolated systemic hypertension. METHODS: In a study of well-controlled hypertensive p...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534050/ https://www.ncbi.nlm.nih.gov/pubmed/26264919 http://dx.doi.org/10.1186/s12968-015-0176-3 |
_version_ | 1782385403558363136 |
---|---|
author | Treibel, Thomas A. Zemrak, Filip Sado, Daniel M. Banypersad, Sanjay M. White, Steven K. Maestrini, Viviana Barison, Andrea Patel, Vimal Herrey, Anna S. Davies, Ceri Caulfield, Mark J. Petersen, Steffen E. Moon, James C. |
author_facet | Treibel, Thomas A. Zemrak, Filip Sado, Daniel M. Banypersad, Sanjay M. White, Steven K. Maestrini, Viviana Barison, Andrea Patel, Vimal Herrey, Anna S. Davies, Ceri Caulfield, Mark J. Petersen, Steffen E. Moon, James C. |
author_sort | Treibel, Thomas A. |
collection | PubMed |
description | BACKGROUND: Diffuse myocardial fibrosis (DMF) is important in cardiovascular disease, however until recently could only be assessed by invasive biopsy. We hypothesised that DMF measured by T1 mapping is elevated in isolated systemic hypertension. METHODS: In a study of well-controlled hypertensive patients from a specialist tertiary centre, 46 hypertensive patients (median age 56, range 21 to 78, 52 % male) and 50 healthy volunteers (median age 45, range 28 to 69, 52 % male) underwent clinical CMR at 1.5 T with T1 mapping (ShMOLLI) using the equilibrium contrast technique for extracellular volume (ECV) quantification. Patients underwent 24-hours Automated Blood Pressure Monitoring (ABPM), echocardiographic assessment of diastolic function, aortic stiffness assessment and measurement of NT-pro-BNP and collagen biomarkers. RESULTS: Late gadolinium enhancement (LGE) revealed significant unexpected underlying pathology in 6 out of 46 patients (13 %; myocardial infarction n = 3; hypertrophic cardiomyopathy (HCM) n = 3); these were subsequently excluded. Limited, non-ischaemic LGE patterns were seen in 11 out of the remaining 40 (28 %) patients. Hypertensives on therapy (mean 2.2 agents) had a mean ABPM of 152/88 mmHg, but only 35 % (14/40) had left ventricular hypertrophy (LVH; LV mass male > 90 g/m(2); female > 78 g/m(2)). Native myocardial T1 was similar in hypertensives and controls (955 ± 30 ms versus 965 ± 38 ms, p = 0.16). The difference in ECV did not reach significance (0.26 ± 0.02 versus 0.27 ± 0.03, p = 0.06). In the subset with LVH, the ECV was significantly higher (0.28 ± 0.03 versus 0.26 ± 0.02, p < 0.001). CONCLUSION: In well-controlled hypertensive patients, conventional CMR discovered significant underlying diseases (chronic infarction, HCM) not detected by echocardiography previously or even during this study. T1 mapping revealed increased diffuse myocardial fibrosis, but the increases were small and only occurred with LVH. |
format | Online Article Text |
id | pubmed-4534050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45340502015-08-19 Extracellular volume quantification in isolated hypertension - changes at the detectable limits? Treibel, Thomas A. Zemrak, Filip Sado, Daniel M. Banypersad, Sanjay M. White, Steven K. Maestrini, Viviana Barison, Andrea Patel, Vimal Herrey, Anna S. Davies, Ceri Caulfield, Mark J. Petersen, Steffen E. Moon, James C. J Cardiovasc Magn Reson Research BACKGROUND: Diffuse myocardial fibrosis (DMF) is important in cardiovascular disease, however until recently could only be assessed by invasive biopsy. We hypothesised that DMF measured by T1 mapping is elevated in isolated systemic hypertension. METHODS: In a study of well-controlled hypertensive patients from a specialist tertiary centre, 46 hypertensive patients (median age 56, range 21 to 78, 52 % male) and 50 healthy volunteers (median age 45, range 28 to 69, 52 % male) underwent clinical CMR at 1.5 T with T1 mapping (ShMOLLI) using the equilibrium contrast technique for extracellular volume (ECV) quantification. Patients underwent 24-hours Automated Blood Pressure Monitoring (ABPM), echocardiographic assessment of diastolic function, aortic stiffness assessment and measurement of NT-pro-BNP and collagen biomarkers. RESULTS: Late gadolinium enhancement (LGE) revealed significant unexpected underlying pathology in 6 out of 46 patients (13 %; myocardial infarction n = 3; hypertrophic cardiomyopathy (HCM) n = 3); these were subsequently excluded. Limited, non-ischaemic LGE patterns were seen in 11 out of the remaining 40 (28 %) patients. Hypertensives on therapy (mean 2.2 agents) had a mean ABPM of 152/88 mmHg, but only 35 % (14/40) had left ventricular hypertrophy (LVH; LV mass male > 90 g/m(2); female > 78 g/m(2)). Native myocardial T1 was similar in hypertensives and controls (955 ± 30 ms versus 965 ± 38 ms, p = 0.16). The difference in ECV did not reach significance (0.26 ± 0.02 versus 0.27 ± 0.03, p = 0.06). In the subset with LVH, the ECV was significantly higher (0.28 ± 0.03 versus 0.26 ± 0.02, p < 0.001). CONCLUSION: In well-controlled hypertensive patients, conventional CMR discovered significant underlying diseases (chronic infarction, HCM) not detected by echocardiography previously or even during this study. T1 mapping revealed increased diffuse myocardial fibrosis, but the increases were small and only occurred with LVH. BioMed Central 2015-08-12 /pmc/articles/PMC4534050/ /pubmed/26264919 http://dx.doi.org/10.1186/s12968-015-0176-3 Text en © Treibel et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Treibel, Thomas A. Zemrak, Filip Sado, Daniel M. Banypersad, Sanjay M. White, Steven K. Maestrini, Viviana Barison, Andrea Patel, Vimal Herrey, Anna S. Davies, Ceri Caulfield, Mark J. Petersen, Steffen E. Moon, James C. Extracellular volume quantification in isolated hypertension - changes at the detectable limits? |
title | Extracellular volume quantification in isolated hypertension - changes at the detectable limits? |
title_full | Extracellular volume quantification in isolated hypertension - changes at the detectable limits? |
title_fullStr | Extracellular volume quantification in isolated hypertension - changes at the detectable limits? |
title_full_unstemmed | Extracellular volume quantification in isolated hypertension - changes at the detectable limits? |
title_short | Extracellular volume quantification in isolated hypertension - changes at the detectable limits? |
title_sort | extracellular volume quantification in isolated hypertension - changes at the detectable limits? |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534050/ https://www.ncbi.nlm.nih.gov/pubmed/26264919 http://dx.doi.org/10.1186/s12968-015-0176-3 |
work_keys_str_mv | AT treibelthomasa extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits AT zemrakfilip extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits AT sadodanielm extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits AT banypersadsanjaym extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits AT whitestevenk extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits AT maestriniviviana extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits AT barisonandrea extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits AT patelvimal extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits AT herreyannas extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits AT daviesceri extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits AT caulfieldmarkj extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits AT petersensteffene extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits AT moonjamesc extracellularvolumequantificationinisolatedhypertensionchangesatthedetectablelimits |